Mortality risk of femoropopliteal paclitaxel-coated devices remains inconclusive

Podobne knjige/članki

• One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease
  od: Soga, Yoshimitsu, et al.
  Izdano: (2020)
• Inverse association of diabetes and dialysis with the severity of femoropopliteal lesions and chronic total occlusion: a cross-sectional study of 2056 cases
  od: Takahara, Mitsuyoshi, et al.
  Izdano: (2020)
• Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases
  od: Takahara, Mitsuyoshi, et al.
  Izdano: (2019)
• Presentation Pattern of Lower Extremity Endovascular Intervention versus Percutaneous Coronary Intervention
  od: Takahara, Mitsuyoshi, et al.
  Izdano: (2020)
• Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease
  od: Ceazón T Edwards, et al.
  Izdano: (2021-07-01)